Trial · NCT03120949
Results by group690
Each measurement the trial posted, group by group, in the words and numbers it posted.
41 to 60 of 690
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Incidence of Treatment-Emergent Serious Adverse Events (SAEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 1: OKZ 64 mg q4w + MTX | Infections and infestations | 40 | Participants | |
| Incidence of Treatment-Emergent Serious Adverse Events (SAEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 2: OKZ 64 mg q2w + MTX | Infections and infestations | 47 | Participants | |
| Incidence of Treatment-Emergent Serious Adverse Events (SAEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 1: OKZ 64 mg q4w + MTX | Infections and infestations: Pneumonia | 7 | Participants | |
| Incidence of Treatment-Emergent Serious Adverse Events (SAEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 2: OKZ 64 mg q2w + MTX | Infections and infestations: Pneumonia | 7 | Participants | |
| Incidence of Treatment-Emergent Serious Adverse Events (SAEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 1: OKZ 64 mg q4w + MTX | Infections and infestations: Cellulitis | 7 | Participants | |
| Incidence of Treatment-Emergent Serious Adverse Events (SAEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 2: OKZ 64 mg q2w + MTX | Infections and infestations: Cellulitis | 4 | Participants | |
| Incidence of Treatment-Emergent Serious Adverse Events (SAEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 1: OKZ 64 mg q4w + MTX | Infections and infestations: Erysipelas | 5 | Participants | |
| Incidence of Treatment-Emergent Serious Adverse Events (SAEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 2: OKZ 64 mg q2w + MTX | Infections and infestations: Erysipelas | 4 | Participants | |
| Incidence of Treatment-Emergent Serious Adverse Events (SAEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 1: OKZ 64 mg q4w + MTX | Infections and infestations: COVID-19 | 1 | Participants | |
| Incidence of Treatment-Emergent Serious Adverse Events (SAEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 2: OKZ 64 mg q2w + MTX | Infections and infestations: COVID-19 | 3 | Participants | |
| Incidence of Treatment-Emergent Serious Adverse Events (SAEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 1: OKZ 64 mg q4w + MTX | Infections and infestations: Pyelonephritis acute | 2 | Participants | |
| Incidence of Treatment-Emergent Serious Adverse Events (SAEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 2: OKZ 64 mg q2w + MTX | Infections and infestations: Pyelonephritis acute | 2 | Participants | |
| Incidence of Treatment-Emergent Serious Adverse Events (SAEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 1: OKZ 64 mg q4w + MTX | Infections and infestations: COVID-19 pneumonia | 2 | Participants | |
| Incidence of Treatment-Emergent Serious Adverse Events (SAEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 2: OKZ 64 mg q2w + MTX | Infections and infestations: COVID-19 pneumonia | 1 | Participants | |
| Incidence of Treatment-Emergent Serious Adverse Events (SAEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 1: OKZ 64 mg q4w + MTX | Infections and infestations: Pyelonephritis | 2 | Participants | |
| Incidence of Treatment-Emergent Serious Adverse Events (SAEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 2: OKZ 64 mg q2w + MTX | Infections and infestations: Pyelonephritis | 1 | Participants | |
| Incidence of Treatment-Emergent Serious Adverse Events (SAEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 1: OKZ 64 mg q4w + MTX | Infections and infestations: Sepsis | 0 | Participants | |
| Incidence of Treatment-Emergent Serious Adverse Events (SAEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 2: OKZ 64 mg q2w + MTX | Infections and infestations: Sepsis | 3 | Participants | |
| Incidence of Treatment-Emergent Serious Adverse Events (SAEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 1: OKZ 64 mg q4w + MTX | Infections and infestations: Abscess limb | 1 | Participants | |
| Incidence of Treatment-Emergent Serious Adverse Events (SAEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 2: OKZ 64 mg q2w + MTX | Infections and infestations: Abscess limb | 1 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03120949/results?page=3